- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02147483
Mindfulness-Based Relapse Prevention for Alcohol Use Disorders in Remission (MBRP)
Mindfulness-Based Relapse Prevention and Stress Reactivity in Alcohol Dependent Individuals: A Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Stress exposure increases psychological and physiological arousal and can lead to negative health outcomes. An impaired ability to self-regulate in response to stress contributes to the development of alcohol use disorders and relapse. Mindfulness, a state of present-focused attention and awareness, can be systematically learned through meditative practice to improve self-regulation of emotional, physiological and behavioral responses to stress. Mindfulness meditation further facilitates a balance of mind and body thereby increasing one's ability to respond proactively and effectively to daily events. Research evidence suggests a strong association between mindfulness and positive indicators of well-being which include reductions in fear, anxiety, anger, and better physiological recovery from stress.
Given the importance of self-regulation in the development and progression of alcohol use disorders and relapse, a new approach to substance use treatment, Mindfulness-Based Relapse Prevention (MBRP), was developed. Traditionally, MBRP is an eight-week outpatient treatment program, which integrates core aspects of Relapse Prevention (RP) practices with practices adapted from Mindfulness-Based Stress Reduction (MBSR) and Mindfulness-Based Cognitive Therapy. The mindfulness practices in MBRP are designed to increase acceptance and tolerance of negative emotions, thoughts and physical states thus reducing the need to alleviate associated discomfort through substance use. MBRP also focuses on increasing awareness of triggers and developing more effective coping behaviors in high-risk situations. Among adults with substance use disorders, MBRP has been found to lead to significantly lower rates of substance use, greater decreases in cravings and greater increases in acceptance and acting with awareness than treatment as usual. MBRP has also been found to facilitate more effective coping and self-regulation of negative emotions during early abstinence.
While research indicates that MBRP is effective in reducing substance use relapse, only preliminary research has examined the influence of MBRP on the physiological mechanisms involved in emotion regulation after exposure to stress. Examining these physiological mechanisms is essential because the central and autonomic nervous systems work together to coordinate the self-regulation of attention, cognition and emotion when stressful cues are encountered, such as when a substance dependent individual is exposed to stressful and/or substance related stimuli. Heart rate variability (HRV) is generally seen as an index of emotion regulation. High frequency HRV reflects parasympathetic activation of the autonomic nervous system and the body's ability to exert cognitive control over attention and emotional responding. Higher levels of HRV are associated with greater emotional and behavioral flexibility, and tend to be associated with better mental and physical health outcomes. In contrast, lower levels of HRV are associated with a wide range of medical and psychiatric disorders, including acute and chronic alcohol ingestion, anxiety and depression. Among alcohol dependent individuals, mindfulness training has been found to increase HRV and lower subjective levels of psychological distress in response to stressful cues in the short-term. The proposed study will be the first to examine the long-term effects of MBRP on HRV and self-reported psychological/behavioral functioning. The results will provide a better understanding of the interplay between the psychological and physical mechanisms involved in relapse and help determine whether MBRP has lasting psychological and physiological benefits. In other words, assessing both the psychological and physiological effects of MBRP will provide a more accurate and comprehensive understanding of how mindfulness aids in promoting self-regulation and relapse prevention. Finally, little is known about which types of individuals are most likely to benefit from MBRP. It is necessary to examine individual characteristics (i.e., baseline levels of HRV, trait mindfulness, substance use, anxiety, depression) to determine which characteristics are associated with positive treatment outcomes in both the short and long-term. This knowledge will enable more efficient and effective delivery of the MBRP treatment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University of Virginia School Of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females who have given written informed consent
- 21 years of age or older
- DSM-IV-TR diagnosis of alcohol dependence within the last year, but have abstained from drinking for the last thirty days
- Literate in English and able to read, understand, and complete the rating scales and questionnaires accurately, follow instructions, and make use of mindfulness techniques
- Express a wish to remain abstinent from drinking
- Willingness to participate in mindfulness techniques
- Able to attend all clinic visits without interruption
Exclusion Criteria:
- Any current Axis I DSM-IV-TR psychiatric disorder other than alcohol or nicotine dependence that, in the clinician's opinion, warrants treatment or would preclude safe participation in the protocol, including, but not limited to: psychosis, schizophrenia, dementia, schizotypal personality disorder, borderline personality disorder, bipolar disorder, primary diagnosis of eating disorder, or chronic suicidality or homicidality
- Current use of Antabuse (Disulfiram) to pharmacologically treat alcohol dependence
- Serious medical comorbidity requiring medical intervention or close supervision, including a history of dangerous symptoms of withdrawal from alcohol (e.g., seizures), pacemakers, heart transplant, severe arrhythmias, or active atrial fibrillation
- Suicide attempt in the last thirty days
- Gross neurological disease
- Mental retardation, which will be assessed by the PI, postdoctoral fellows, and doctoral students in clinical psychology)
- Minors below the legal drinking age will not be included.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Treatment as usual
Treatment as usual as prescribed by clinician.
|
Treatment usually provided by clinician
|
|
Experimental: Mindfulness Based Relapse Prevention
Mindfulness based relapse prevention will be provided in eight in person sessions to prevent alcohol use.
|
Mindfulness based relapse prevention therapy provided over eight sessions in person to prevent alcohol relapse.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mindfulness levels
Time Frame: up to 4 months post treatment
|
Difference scores on mindfulness scales (session 04 minus baseline, session 08 minus baseline, two-month follow-up minus baseline, four-month follow-up minus baseline) will be calculated.
2 group (intervention, TAU) x 5 interval (baseline, session 04, session 08, two-months follow-up, four-months follow-up) repeated measures analyses of variance (ANOVAs) will be conducted.
|
up to 4 months post treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
cravings; symptoms of depression, anxiety, and perceived stress; obsessive thoughts of alcohol/compulsive drinking
Time Frame: up to 4 months post treatment
|
Difference scores (session 04 minus baseline, session 08 minus baseline, two-month follow-up minus baseline, four-month follow-up minus baseline) will be calculated for cravings, symptoms of depression, anxiety, perceived stress, obsessive thoughts of alcohol/compulsive drinking.
To test hypotheses 1, 2, and 3, 2 group (intervention, TAU) x 5 interval (baseline, session 04, session 08, two-months follow-up, four-months follow-up) repeated measures analyses of variance (ANOVAs) will be conducted.
|
up to 4 months post treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
drinking behavior
Time Frame: up to 4 months post treatment
|
Difference scores (session 04 minus baseline, session 08 minus baseline, two-month follow-up minus baseline, four-month follow-up minus baseline) will be calculated for total drinks.
2 group (intervention, TAU) x 5 interval (baseline, session 04, session 08, two-months follow-up, four-months follow-up) repeated measures analyses of variance (ANOVAs) will be conducted.
|
up to 4 months post treatment
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16363
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Use Disorders
-
University of Colorado, DenverUnknownAlcohol Use Disorders | Unhealthy Alcohol UseUnited States
-
Spark Biomedical, Inc.National Institute on Alcohol Abuse and Alcoholism (NIAAA); Baylor College... and other collaboratorsRecruitingSubstance Use Disorders | Alcohol Use Disorder | Alcohol Abuse | Substance Use Disorders Alcohol Use Withdrawal StateUnited States
-
Université du Québec à Trois-RivièresCompletedAlcohol Use, Unspecified | Alcohol Use Disorder, MildCanada
-
Women's College HospitalRecruitingAlcohol; Harmful Use | Tobacco Use | Tobacco Use Cessation | Alcohol Use, UnspecifiedCanada
-
Woebot HealthStanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
Indiana UniversityPatient-Centered Outcomes Research InstituteRecruitingAdolescent | Alcohol Use | Mild Alcohol Use Disorder | Mild Substance Use DisorderUnited States
-
University of North Carolina, Chapel HillCompletedAlcohol Use Disorder, Mild | Alcohol Use Disorder, ModerateUnited States
-
Technische Universität DresdenCharite University, Berlin, Germany; Central Institute of Mental Health, MannheimRecruitingAlcoholism | Substance Use Disorders | Alcohol Use Disorder (AUD)Germany
-
Washington State UniversityRecruitingNicotine Use Disorder | Alcohol Use Disorder (AUD)United States
-
Technische Universität DresdenCharite University, Berlin, Germany; Central Institute of Mental Health, MannheimRecruitingAlcoholism | Methamphetamine-dependence | Substance Use Disorders | Cocaine Use Disorder | Alcohol Use Disorder (AUD) | Cannabis Use Disorder | Amphetamine Use DisorderGermany
Clinical Trials on Treatment as usual
-
Universitätsklinikum Hamburg-EppendorfCompletedPerioperative AnxietyGermany
-
University of ChicagoNational Institute of Mental Health (NIMH)Not yet recruitingHIV | Financial Stress
-
South London and Maudsley NHS Foundation TrustCompletedAttention Deficit Hyperactivity DisorderUnited Kingdom
-
McMaster UniversityNot yet recruiting
-
Gaia AGWithdrawnType 2 DiabetesGermany
-
Centre for Addiction and Mental HealthCompleted
-
King's College LondonUnknown
-
University Hospital, AkershusUniversity of OsloActive, not recruiting
-
University of IndianapolisUniversity of Missouri, Kansas City; Missouri State UniversityCompletedHypertension | Diabete Type 2United States
-
Universitat Jaume IConsorcio Hospitalario Provincial de CastellónCompletedDepression | AnxietySpain